title: [Restoration of the quality of life by eliminating and prevention of heartburn by alginate: results of multicenter study "VIA APIA"].
abstract: Was conducted a muIticenter study VIA APIA, in which the impact of gaviscon forte (suspension) on symptoms, general state and quality of life of 148 patients (male 53, female 95, age 42.9 +/- 15.6) with gastroesophageal reflux disease (GERD) were investigated. The patients had undergone clinical evaluation of dynamics of GERD symptoms (Likert scale), general state (Visual Analogue Scale, questionnaire SAN) and quality of life (SF-36). It was shown that 14-days treatment with gaviscon forte provided symptoms relief in 84.5% patients and conducted improvement of general state and quality of life. Gaviscon forte recommended as drug of choice in initial treatment for the first time visited patient with heartburn before endoscopy and for pathogenetic treatment of typical reflux syndrome.
authors: L B
authors: LB
authors: Lazebnik
authors: D S
authors: DS
authors: Bordin
authors: A A
authors: AA
authors: Masharova
authors: G S
authors: GS
authors: Dzhulaĭ
authors: M A
authors: MA
authors: Butov
authors: R A
authors: RA
authors: Abdulkhakov
authors: E Iu
authors: EIu
authors: Eremina
authors: L V
authors: LV
authors: Tarasova
authors: O V
authors: OV
authors: Safonova
authors: L D
authors: LD
authors: Firsova
authors: T S
authors: TS
authors: Kozhurina
mesh_terms: D000328:Adult; D000464:Alginates / Q000008:administration & dosage / Q000627:therapeutic use*; D000536:Aluminum Hydroxide / Q000008:administration & dosage / Q000627:therapeutic use*; D000863:Antacids / Q000008:administration & dosage / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D005764:Gastroesophageal Reflux / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control / Q000523:psychology; D006356:Heartburn / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control / Q000523:psychology; D006801:Humans; D008297:Male; D011446:Prospective Studies; D011788:Quality of Life / Q000523:psychology; D012720:Severity of Illness Index; D012824:Silicic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D017693:Sodium Bicarbonate / Q000008:administration & dosage / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D013535:Suspensions; D016896:Treatment Outcome
chemical_list: D000464:Alginates; D000863:Antacids; D004338:Drug Combinations; D013535:Suspensions; D012824:Silicic Acid; D000536:Aluminum Hydroxide; C007829:alginate, aluminium hydroxide, magnesium trisilicate, sodium bicarbonate drug combination; D017693:Sodium Bicarbonate